We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

1 hedge funds and large institutions have $25 invested in CASI Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

10.18% less ownership

Funds ownership: 10.18% → 0% (-10%)

94% less funds holding

Funds holding: 16 → 1 (-15)

100% less capital invested

Capital invested by funds: $1.06M → $25 (-$1.06M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 15

Holders
1
Holders Change
-15
Holders Change %
-93.75%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Simplex Trading
Simplex Trading
Illinois
+$86

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$839K
2
WP
Woodline Partners
California
-$113K
3
Renaissance Technologies
Renaissance Technologies
New York
-$36.6K
4
Two Sigma Investments
Two Sigma Investments
New York
-$20.2K
5
Bank of America
Bank of America
North Carolina
-$16.9K

CASI Hedge Fund Activity: Q1 2026 in Review

1 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2026, worth a combined $25 — down 100% from $1.06M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of CASI and 0 opened new positions — a net loss of 15 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Simplex Trading, adding an estimated $86. The largest seller was VR Adviser, exiting entirely with an estimated $839K sold.

  • 1 institutional investor held CASI Pharmaceuticals (CASI) as of Q1 2026, down from 16 in Q4 2025.
  • Funds reported $25 of CASI Pharmaceuticals stock for Q1 2026, down 100% quarter-over-quarter.
  • 0 funds opened new CASI Pharmaceuticals positions in Q1 2026 and 15 closed out, a net change of -15 holders.
  • The largest CASI Pharmaceuticals buyer in Q1 2026 was Simplex Trading, an estimated $86 added.
  • The largest CASI Pharmaceuticals seller in Q1 2026 was VR Adviser, an estimated $839K sold.

Based on aggregated 13F filings for Q1 2026.